drugset / Trial / NCT00315003

TELI COM - Telithromycin in Children With Otitis Media

NCT00315003

Phase 3 Terminated 1500 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multinational, randomized (1:1), double-blind, double-dummy, comparative, 2- treatmentgroup study in children (age range: ≥6 months and \<72 months \[\< 6 years of age\]) with AOM.Subjects will be randomized to receive either telithromycin (50 mg/mL) oral suspension 25 mg/kgonce daily for 5 days or azithromycin (40 mg/mL) oral suspension (10 mg/kg once on Day 1, followed by 5 mg/kg once daily on Days 2-5, not to exceed 500 mg onDay 1 and 250 mg/day from Days 2 - 5. Matching placebo suspensions for telithromycin and azithromycin will also be dispensed to provide blinding for the different treatment regimens.Assessments and reporting of safety will be carried out at all visits.

Timeline

Start
2006-01
Primary completion
2006-07
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 5 mg/kg Oral
Subject Telithromycin Small molecule 25 mg/kg Oral